Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

Completed · Phase 3 · Has a placebo group

Conditions studied: Advanced, Metastatic Breast Cancer

In brief

The primary purpose of this study was to assess the efficacy of ribociclib, as measured by progression free survival (PFS), in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who received no prior treatment for advanced disease.

Key facts

Study ID
NCT01958021
Run by
Novartis Pharmaceuticals
People needed
668
Starts
2013-12-17
Expected to finish
2023-03-16
Last updated by the study team
2025-03-07

Who can join

Age: 18 and older, up to 100. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.